Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Startup Spotlight: Flagship Pioneering’s Sigilon gets a new CEO

  • Kate Sheridan

By Kate Sheridan Aug. 14, 2018

Reprints
STAT SPOTLIGHT
Alex Hogan/STAT

A Cambridge, Mass., biotech startup working to unlock new applications for cell therapies — particularly for type 1 diabetes — is getting new leadership.

Dr. Rogerio Vivaldi, formerly at Sanofi’s Bioverativ, took the helm of of Sigilon Therapeutics on Aug. 1, the company announced Tuesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
A baby with a disease gene or no baby…
A baby with a disease gene or no baby at all: Genetic testing of embryos creates…
A quest to explain the whooshing in her head
A quest to explain the whooshing in her head
Biden administration goes easy on Medicare Advantage insurers after…
Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds

Recommended Stories